eprintid: 1503787
rev_number: 36
eprint_status: archive
userid: 608
dir: disk0/01/50/37/87
datestamp: 2021-11-05 14:37:51
lastmod: 2021-11-06 00:09:31
status_changed: 2021-11-05 14:37:51
type: book_section
metadata_visibility: show
creators_name: Una-Cidon, E
creators_name: Adeleke, S
creators_name: Masters, B
creators_name: Wood, V
title: Gefitinib
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
keywords: Targeted agent, personalised medicine, precision medicine
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
abstract: Gefitinib is a small molecule that specifically inhibits the tyrosine kinase (TK) activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the adenosine triphosphate (ATP) binding site. About 10% of patient with non-small cell lung cancer (NSCLC) in the US and about 35% in East Asia have EGFR mutations. [1] Hence gefitinib and the other EGFR inhibitor erlotinib are inevitably important in treatment of NSCLC, of the adenocarcinoma variant with the above mutation.
date: 2016-05-02
date_type: published
publisher: nova science publishers
official_url: https://novapublishers.com/shop/the-easy-book-of-cancer-pharmacology/
oa_status: green
full_text_type: other
language: eng
verified: verified_manual
elements_id: 1142237
isbn_13: 9781634850384
publication_declined: 2021-11-06T00:09:31GMT
lyricists_name: Adeleke, Olusola
lyricists_id: OADEL92
actors_name: Barczynska, Patrycja
actors_id: PBARC91
actors_role: owner
full_text_status: public
number: 22
book_title: The Easy Book of Cancer Pharmacology
edition: 1st
editors_name: Una-Cidon, E
citation:        Una-Cidon, E;    Adeleke, S;    Masters, B;    Wood, V;      (2016)    Gefitinib.                    In: Una-Cidon, E, (ed.) The Easy Book of Cancer Pharmacology.    nova science publishers       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/1503787/1/Adeleke_Gefitinib%20formatted.pdf